GO
Loading...

Roche Holding AG

More

  • Biotechs rallied after Roche Holding AG agreed to buy InterMune Inc for $8.3 billion in cash, the latest vote of confidence in a sector that many, including Federal Reserve Chair Janet Yellen, are worried is overvalued. InterMune jumped 36 percent to $73.00, with the Nasdaq Biotech index up 2.4 percent.

  • *Roche to buy InterMune for $8.3 billion. *U.S. investors took cues from Europe, where an index of major shares rose 0.7 percent after European Central Bank President Mario Draghi said Friday the ECB was prepared to respond with available tools if inflation dropped further.

  • US stock futures gain on M&A, hope for ECB stimulus Monday, 25 Aug 2014 | 8:36 AM ET

    U.S. stock-index futures rose on Monday, following European shares higher, as traders digested comments by the Fed's Yellen and the ECB's Draghi.

  • *Roche to buy InterMune for $8.3 billion. *U.S. investors took cues from Europe, where an index of major shares rose 0.7 percent after European Central Bank President Mario Draghi said Friday the ECB was prepared to respond with available tools if inflation dropped further.

  • Roche is buying biotech company InterMune for $74 per share, reports CNBC's Meg Tirrell.

  • LOS ANGELES, Aug 25- U.S. regulators are likely to approve Merck& Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.

  • Surani Fernando, EMEA deputy editor at Biopharm Insight, says she was "surprised" at the value of Roche's $8.3 billion purchase of Intermune.

  • *Euro STOXX 50 index rises 1.1 percent. LONDON, Aug 25- European shares rose in morning trading on Monday, with market sentiment improving after comments by European Central Bank President Mario Draghi raised expectations of further policy easing.

  • *Deal boosts Roche presence in respiratory medicine. LONDON/ ZURICH, Aug 24- Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector.

  • Roche to purchase InterMune in $8.3 billion deal Sunday, 24 Aug 2014 | 12:27 PM ET

    Biotech firm Roche announced plans Sunday to buy InterMune for $8.3 billion on a fully diluted basis in an all-cash transaction.

  • Roche to buy U.S. biotech firm InterMune for $8.3 bln Sunday, 24 Aug 2014 | 12:25 PM ET

    LONDON, Aug 24- Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector, Roche said on Sunday.

  • SAN FRANCISCO, Aug 22- Genentech Inc is on the hunt for partnerships and investment opportunities in medical-technology startups, Chief Executive Officer Ian Clark told Reuters, underscoring the industry's growing interest in digital healthcare.

  • Investors looking at stock prices on screens in a securities exchange in Shanghai.

    Asian equities traded mixed on Monday as a cautious sentiment set in after fresh conflict in Ukraine at the weekend.

  • Chugai denied over the weekend that it was in talks with Roche over a buyout but investors dismissed the statement, sending the shares limit-up in early trade, to a record 4,015 yen, before closing up 15.4 percent at 3,825 yen.

  • TOKYO, Aug 18- Japan's Nikkei ended flat on Monday in thin trade as geopolitical tensions dulled risk appetite, but Chugai Pharmaceutical jumped on a media report that Roche Holding AG's may be close to sealing a deal to take full ownership of the Japanese drugmaker. The Nikkei was flat at 15,322.60 in choppy trade.

  • Chugai soars 20% on talk of Roche buyout Monday, 18 Aug 2014 | 1:29 AM ET
    A man is reflected in an electric quotation board flashing chart of the Nikkei index of the Tokyo Stock Exchange.

    Chugai shares rose 21 percent following a media report that Roche Holding AG is in talks to buy the almost 40 percent stake in the Japanese firm.

  • Is a Roche-Chugai merger on the cards?     Sunday, 17 Aug 2014 | 11:31 PM ET

    Milind Sabnis, Associate Director for Healthcare Practice at Frost & Sullivan, discusses news that Roche is looking to acquire Japanese drug giant Chugai Pharmaceutical for about $10 billion.

  • TOKYO, Aug 18- Japan's Nikkei was choppy on Monday morning as geopolitical tensions checked risk appetite, but Chugai Pharmaceutical jumped on a media report that Roche Holding AG's may be close to sealing a deal to gain full ownership of the Japanese drugmaker.

  • LOS ANGELES, Aug 17- Biotech drug production techniques based on plants, which may prove to be faster, higher yielding and cheaper than current methods using mammalian cells, haven't caught on with the biggest pharmaceutical companies.

  • NORWICH, England, Aug 17- Pampering leafcutter ants with fragrant rose petals and fresh oranges may seem an unlikely way to rescue modern medicine, but scientists at a lab in eastern England think it's well worth trying.